This multicenter trial tested the effect of empirical antifungal treatment in febrile intensive care unit patients. Investigators
randomly assigned 270 patients with fever despite taking broad-spectrum antibiotics to either fluconazole, 800 mg/d, or placebo
for 2 weeks. About 40% of patients in each group achieved all 4 components of successful treatment: resolution of fever, no
invasive fungal infection, no stopping therapy because of toxicity, and no need for a nonstudy systemic antifungal medication.
Compared with placebo, empirical antifungal fluconazole therapy had no effect in high-risk intensive care unit patients.